38 39 To receive in-depth analysis of digital transformation trends every week subscribe to our newsletter: www.innovator.news knowledge with proprietary questions whose answers are the massive swings in valuation is that the data shows they shared exclusively with the integrator. might have a drug that works a little bit on Alzheimer’s, which has nearly immeasurable economic value,” says All these services will be provided free of charge to Alzhei- Berkowitz. “The other thing they proved is that there is mer’s federation members and will serve as a key proof of interesting data in the drug trial base.” concept for this. There is a huge data store that is locked up that has very Berkowitz says he thinks it will be a compelling proposition meaningful insights on what could be effective treatments, to biotech companies working on Alzheimer’s drugs. Take says Berkowitz. “We are aiming to recruit significant the case of Biogen. Initial trials of its drug Aducanumab neurological disease biotech companies to share insights failed when it was judged to be futile” and the trials were to accelerate treatments for this horrible and stubborn- stopped, causing Biogen’s stock to drop and costing it over ly untreatable disease. With an insight federation, the $20 billion in market cap. Then new data surfaced, which opportunities far outweigh the risks. It is time to try new when added into the drug trial data, indicated that the approaches to stop this slow-moving epidemic.” drug could actually work. The company had a discussion with the U.S. Food & Drug Administration (FDA) and is J.L.S soon submitting the drug for approval, causing its stock to rise. Biogen then reported the findings of its study at conference and its stock soared yet again. “The reason for